Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. Sonpavde on the Next Steps for Atezolizumab in Urothelial Carcinoma

March 22nd 2018

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses the next steps for the prognostic model for atezolizumab (Tecentriq) in patients with urothelial carcinoma.

Novel Lenvatinib Combinations Tested in Frontline RCC

March 22nd 2018

The current standard-of-care therapy for patients with clear cell renal cell carcinoma is sunitinib, but many patients relapse or don't have responses to the drug.

Dr. Den Discusses Bone-Targeting Agents in Prostate Cancer

March 20th 2018

Robert B. Den, MD, associate professor of radiation oncology, Thomas Jefferson University Hospital, discusses bone-targeting agents in prostate cancer.

Dr. Plimack on the Growth of Immunotherapy in Bladder Cancer

March 16th 2018

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the growth of immunotherapy for the treatment of patients with bladder cancer.

Expert Highlights Immunotherapy Success in GU Cancers

March 16th 2018

Ani S. Balmanoukian, MD, discusses developments in genitourinary malignancies with promising immunotherapy breakthroughs in renal cell carcinoma and urothelial carcinoma.

FDA Grants Erdafitinib Breakthrough Designation for Urothelial Carcinoma

March 15th 2018

The FDA has granted a breakthrough therapy designation to erdafitinib for the treatment of metastatic urothelial carcinoma.

Chemotherapy May Be Vital to Long-Term Immunotherapy Efficacy in Bladder Cancer

March 14th 2018

Parminder Singh, MD, discusses the potential of immunotherapy, the importance of sequencing to avoid disease progression, and the use of chemotherapy and radiation therapy to reach an unmet need in muscle-invasive bladder cancer.

Dr. Bosse Discusses Bone-Targeted Agents in RCC

March 13th 2018

Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses bone-targeted agents for patients with renal cell carcinoma (RCC).

Managing Advanced Prostate Cancer in the Future

March 13th 2018

Hereditary Prostate Cancer Testing in Practice

March 13th 2018

Improvements in Detecting and Treating Metastatic CRPC

March 13th 2018

Utilizing AR-Targeted Therapies in CRPC

March 13th 2018

Assessing Treatment Response in M0 CRPC

March 13th 2018

Other Emerging Combination Approaches in RCC

March 13th 2018

AR-Targeted Therapies in CRPC

March 13th 2018

Treatment Goals in M0 CRPC

March 13th 2018

CRPC: Goals of Imaging for the Detection of Metastasis

March 13th 2018

Guidelines for Early Detection of Metastasis in CRPC

March 13th 2018

Treatment Challenges in Nonmetastatic CRPC

March 13th 2018

Detecting Newly Diagnosed Metastatic Prostate Cancer

March 13th 2018